Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in Tumors

Access Course


538f50fa-48f9-4b55-a706-f9a2c75c85d9.jpgWhat are the implications for NSCLC, colorectal cancer, and other tumors?

This activity is intended for oncologists and pathologists.

The goal of this activity is to improve the adoption of evidence-based medicine by clarifying when the use of biomarkers is necessary to predict treatment response or when biomarkers do not inform practice.



Approximate Time to Complete: 40 minutes


Credit Available: March 29, 2017- March 29, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the potential biomarkers being examined to predict response to cancer immunotherapies
  • Have increased knowledge regarding the clinical trial data on the utility of biomarkers to guide treatment with cancer immunotherapies
  • Have greater competence related to determining when a biomarker is not necessary to guide treatment selection in patients with advanced cancers